Literature DB >> 10323777

Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice.

G Franceschini1, L Calabresi, G Chiesa, C Parolini, C R Sirtori, M Canavesi, F Bernini.   

Abstract

The ability of HDL to remove cholesterol from peripheral cells and drive it to the liver for excretion is believed to explain most of the strong inverse correlation between plasma HDL cholesterol levels and coronary heart disease. Carriers of the ApoA-IMilano (A-IM) mutant have a severe hypoalphalipoproteinemia but are not at increased risk for premature of coronary heart disease. To explain this apparent paradox, we compared the capacity of serum from A-IM and control subjects to extract cholesterol from Fu5AH cells. Because the A-IM carriers are all heterozygotes for the mutation, we also compared the cholesterol efflux capacity of serum from transgenic mice expressing A-IM or wild-type ApoA-I (A-IWT), in the absence of murine ApoA-I. In the whole series of human or mouse sera, cholesterol efflux was significantly correlated with several HDL-related parameters; after adjustment for concomitant variables, the only parameter that remained significantly correlated with cholesterol efflux was the serum ApoA-I concentration (r2=0.85 in humans and 0.84 in mice). The same was true when samples from control subjects, A-IM carriers, A-IWT or A-IM mice were analyzed separately. Cholesterol efflux to sera from the A-IM carriers was only reduced slightly compared with control sera (25.0+/-4.2% versus 30.4+/-3.3%), although there was a large reduction (-45%) in the serum ApoA-I concentration in the former. Cholesterol efflux was also lower to sera from A-IM than A-IWT mice (15.6+/-3.8% versus 30. 1+/-7.1%), but less than expected from the 70% reduction in serum ApoA-I concentration. A relative efflux potential of serum was calculated in each group as the slope of the regression line fitting cholesterol efflux to ApoA-I concentrations. Therefore, the relative efflux potential reflects the relative efficiency of ApoA-I in determining cell cholesterol efflux. The relative efflux potential of mouse and human sera was in the following order: A-IM mice>A-IM carriers>A-IWT mice=control subjects, suggesting a gene-dosage effect of the A-IM mutation on the efficiency of serum to extract cholesterol from cells. The high efficiency of A-IM-containing HDL for cell cholesterol uptake would result in an improved reverse cholesterol transport in the A-IM carriers, possibly explaining the low susceptibility to atherosclerosis development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323777     DOI: 10.1161/01.atv.19.5.1257

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  27 in total

1.  Molecular belt models for the apolipoprotein A-I Paris and Milano mutations.

Authors:  A E Klon; M K Jones; J P Segrest; S C Harvey
Journal:  Biophys J       Date:  2000-09       Impact factor: 4.033

Review 2.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 3.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

4.  Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice.

Authors:  Lai Wang; Behrooz G Sharifi; Theresa Pan; Lei Song; Ada Yukht; Prediman K Shah
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

Review 5.  Recombinant high-density lipoprotein formulations.

Authors:  Esad Vucic; Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

6.  Emerging HDL-based therapies for atherothrombotic vascular disease.

Authors:  Prediman K Shah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-02

7.  Tweaking the cholesterol efflux capacity of reconstituted HDL.

Authors:  Cheng-I J Ma; Jennifer A Beckstead; Airlia Thompson; Anouar Hafiane; Rui Hao Leo Wang; Robert O Ryan; Robert S Kiss
Journal:  Biochem Cell Biol       Date:  2012-05-18       Impact factor: 3.626

Review 8.  Progress in HDL-based therapies for atherosclerosis.

Authors:  Kuang-Yuh Chyu; Anish Peter; Prediman K Shah
Journal:  Curr Atheroscler Rep       Date:  2011-10       Impact factor: 5.113

9.  Apolipoprotein A-I Helsinki promotes intracellular acyl-CoA cholesterol acyltransferase (ACAT) protein accumulation.

Authors:  Juan D Toledo; Horacio A Garda; Laura V Cabaleiro; Angela Cuellar; Magali Pellon-Maison; Maria R Gonzalez-Baro; Marina C Gonzalez
Journal:  Mol Cell Biochem       Date:  2013-03-03       Impact factor: 3.396

Review 10.  Lipoproteins, cholesterol homeostasis and cardiac health.

Authors:  Tyler F Daniels; Karen M Killinger; Jennifer J Michal; Raymond W Wright; Zhihua Jiang
Journal:  Int J Biol Sci       Date:  2009-06-29       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.